Immunotherapy for hayfever.
Durham
S R
SR
Imperial College School of Medicine, National Heart and Lung Institute, London, UK. s.durham@rbh.nthames.nhs.uk
Walker
S
S
D000286:Administration, Sublingual; D000328:Adult; D000485:Allergens / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D001986:Bronchial Spasm / Q000209:etiology; D002648:Child; D002986:Clinical Trials as Topic; D003888:Desensitization, Immunologic; D005500:Follow-Up Studies; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis; D007267:Injections; D008925:Mites; D011058:Pollen; D012221:Rhinitis, Allergic, Perennial / Q000628:therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D012449:Safety; D012621:Seasons
D000485:Allergens; D018926:Anti-Allergic Agents; D007073:Immunoglobulin E